Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|January 24, 2012
Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancerCesare Gridelli, Thomas Brodowicz, Corey J Langer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2010
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancerGiorgio Scagliotti, Thomas Brodowicz, Frances A Shepherd, et al.
Plos One|August 7, 2015
The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine LeiomyosarcomaRichard Schwameis, Christoph Grimm, Edgar Petru, et al.
ESMO Open|August 2, 2017
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Gerald W Prager, et al.
Wiener Klinische Wochenschrift|October 22, 2010
Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trialNegar Fakhrai, Claudia Ebm, Wolfgang J Kostler, et al.
International Journal of Cancer|November 6, 2003
Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neuJoanna Jasinska, Stefan Wagner, Christian Radauer, et al.
Breast Cancer Research and Treatment|September 22, 2009
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)Antoaneta Tomova, Rupert Bartsch, Thomas Brodowicz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancerStefan Kasper, Caroline Foch, Diethelm Messinger, et al.
The International Journal of Artificial Organs|September 30, 2014
Hepatic dysfunction contributes to coagulation disturbances in patients undergoing whole body hyperthermia by use of extracorporeal circulationNina Worel, Paul Knöbl, Georgios Karanikas, et al.
Breast Cancer Research and Treatment|October 24, 2003
Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriersChristoph C Zielinski, Alexandra C Budinsky, Teresa M U Wagner, et al.
Pageof 9